Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (HALO)
NASDAQ:HALO
HALO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$37.73 - $66.00
Previous CloseN/A
Volume1.23M
Average Volume (3M)1.68M
Market Cap
$7.44B
Enterprise Value$7.11B
Total Cash (Recent Filing)$55.18M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)17.5
Beta0.92
Next Earnings
May 13, 2025EPS Estimate
0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.43
Shares Outstanding123,533,310
10 Day Avg. Volume1,876,188
30 Day Avg. Volume1,683,636
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)N/A
Price to Sales (P/S)7.90
Price to Cash Flow (P/CF)11.20
P/FCF Ratio11.20
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.30
Enterprise Value/Ebitda10.99
Forecast
1Y Price Target
$67.50Price Target Upside12.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
---
Halozyme News
See All HALO News
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceHALO’s 4Q24 results exceeded expectations and management reiterated previously-issued 2025 guidance.
Patent Dispute ResolutionSuccessfully defending its patents could lead to potential licensing revenues from Merck, bolstering its financial position and potentially implying additional avenues of revenues from other drugs where companies are looking to develop injectable versions.
Bears Say
Biosimilar CompetitionA SQ formulation of Keytruda is unlikely to provide significant commercial protection from biosimilars based on prior precedent with Roche's SQ Herceptin/Rituxan launches ahead of biosimilar competition.
Patent Dispute RiskIf Merck's challenge prevails, Halozyme might lose out on potential income and therefore raise concerns over the validity/defensibility of HALO's subQ co-formulation patents.
---
Ownership Overview
1.09% Insiders
31.16% Mutual Funds
23.94% Other Institutional Investors
12.74% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HALO FAQ
What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest stock price was $37.73 and its highest was $66.00 in the past 12 months.
What is Halozyme Therapeutics’s market cap?
Halozyme Therapeutics’s market cap is $7.44B.
When is Halozyme Therapeutics’s upcoming earnings report date?
Halozyme Therapeutics’s upcoming earnings report date is May 13, 2025 which is in 28 days.
How were Halozyme Therapeutics’s earnings last quarter?
Halozyme Therapeutics released its earnings results on Feb 18, 2025. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.158 by $0.102.
Is Halozyme Therapeutics overvalued?
According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued.
Does Halozyme Therapeutics pay dividends?
Halozyme Therapeutics does not currently pay dividends.
What is Halozyme Therapeutics’s EPS estimate?
Halozyme Therapeutics’s EPS estimate is 0.95.
How many shares outstanding does Halozyme Therapeutics have?
Halozyme Therapeutics has 123,533,310 shares outstanding.
What happened to Halozyme Therapeutics’s price movement after its last earnings report?
Halozyme Therapeutics reported an EPS of $1.26 in its last earnings report, beating expectations of $1.158. Following the earnings report the stock price went down -0.225%.
Which hedge fund is a major shareholder of Halozyme Therapeutics?
Currently, no hedge funds are holding shares in HALO
---
Halozyme Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$67.50 (12.09% Upside)
$67.50 (12.09% Upside)
Blogger Sentiment
Bullish
HALO Sentiment 92%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 161.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.15%
12-Months-Change
Fundamentals
Return on Equity
198.42%
Trailing 12-Months
Asset Growth
24.84%
Trailing 12-Months
Company Description
Halozyme Therapeutics
Halozyme Therapeutics, Inc. (HALO) is a biotechnology company that focuses on developing and commercializing products that target the extracellular matrix for the enhancement of the delivery of drugs and the treatment of tumors. The company operates primarily in the healthcare sector and is known for its proprietary enzyme technology, including the ENHANZE drug delivery platform, which is designed to facilitate the subcutaneous delivery of biologics, potentially improving patient experience and outcomes.
---
HALO Company Deck
---
HALO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, with record-breaking revenue, strong growth in key products, and an optimistic outlook for 2025 and beyond. While there were some setbacks, such as the delay in Amivantamab subcutaneous approval and temporary royalty rate impacts, these were overshadowed by the overall strong financial performance and strategic achievements.Read More>---
HALO Revenue Breakdown
54.01% Royalties
36.28% Product sales
9.71% Revenues under collaborative agreements
---
HALO Stock 12 Month Forecast
Average Price Target
$67.50
▲(12.09% Upside)
Technical Analysis
Corcept Therapeutics
―
Jazz Pharmaceuticals
―
Madrigal Pharmaceuticals
―
Ascendis Pharma
―
Roivant Sciences
―
Best Analysts Covering HALO
1 Year
1 Year Success Rate
19/20 ratings generated profit
1 Year Average Return
+25.61%
reiterated a buy rating last month
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +25.61% per trade.
---